AstraZeneca Pharma Reports 27% Profit Decline in Q2
AstraZeneca Pharma India reported a 27% decline in net profit for Q2 2024, amounting to Rs 38 crore. This is a drop from Rs 52 crore in the same quarter last year. Despite increased revenue of Rs 408 crore, the company's stock fell by 3.74% on the BSE.
- Country:
- India
AstraZeneca Pharma India reported a significant 27% decrease in net profit for the second quarter ending on September 30, 2024. The net profit amounted to Rs 38 crore, a steep decline from Rs 52 crore in the same period the previous year.
Despite the downturn in profit, the company's revenue from operations experienced an uptick, reaching Rs 408 crore, compared to Rs 311 crore in the corresponding timeframe last year, according to a regulatory filing by the firm.
Consequently, shares of AstraZeneca Pharma India fell by 3.74%, closing at Rs 7,133.10 on the Bombay Stock Exchange (BSE).
ALSO READ
-
Cleaner Kitchens, Polluted Skies: Hidden Health Cost of India’s Electricity Boom
-
Japan-Backed ILO Projects Help 23,000 Workers Gain Rights and Fight Child Labour
-
India's Delicate Balancing Act: Navigating Energy Security Amid Middle Eastern Tensions
-
India Gears Up for Glory: Asian Games 2026 Preview
-
India Defends Energy Policy Amidst Rising Tariff Threats from U.S.
Google News